Compare Cloudflare Inc (NET) vs Tango Therapeutics Inc. (TNGX) Price & Performance

Cloudflare (NET) trades at $347.76, down 0.83% on the day, but maintains strong technical momentum with bullish moving averages. The company shows impressive revenue growth from $975M in 2022 to $2.17B in 2025, though it remains unprofitable with a -8.21% net margin. Recent product launches including Cloudflare Basin and post-quantum certificate authority demonstrate continued innovation in the connectivity cloud space.

While valuation metrics appear stretched with P/S of 45.42, strong analyst support (70.7% buy ratings) and consistent earnings beats suggest growth potential. Key risks include persistent profitability challenges and high valuation multiples that leave little room for execution missteps. The stock trades near consensus price target of $333.24, indicating limited near-term upside potential.

TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.

Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.